Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Ultragenyx: 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/05/2018 | 10:17pm CET

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $87.3 million in its third quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $1.74.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.94 per share.

The biotechnology company posted revenue of $11.8 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $11.2 million.

Ultragenyx shares have increased 14 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $53.10, a climb of 7 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
11/15ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/14ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
11/14ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
11/12ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/09ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
11/06ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
11/05ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
11/05ULTRAGENYX : 3Q Earnings Snapshot
AQ
11/05Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
GL
11/01Lilly buys Siga's Priority Review voucher gained via smallpox approval
AQ
More news
News from SeekingAlpha
11/14Ultragenyx on go with U.S. marketing application for UX007 for mid-2019; shar.. 
11/06Ultragenyx Pharmaceutical, Inc. (RARE) CEO Emil Kakkis on Q3 2018 Results - E.. 
11/05Ultragenyx Pharmaceutical beats by $0.22, revenue in-line 
11/04Notable earnings after Monday?s close 
10/29Ultragenyx Fails Trial, But Its Long-Term Track Can't Be Dismissed 
Financials ($)
Sales 2018 49,7 M
EBIT 2018 -376 M
Net income 2018 -202 M
Finance 2018 291 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 43,4x
EV / Sales 2019 21,5x
Capitalization 2 447 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 70,5 $
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC4.31%2 447
GILEAD SCIENCES-1.52%91 265
VERTEX PHARMACEUTICALS9.82%42 060
REGENERON PHARMACEUTICALS-10.29%35 862
GENMAB-10.20%8 631
NEUROCRINE BIOSCIENCES, INC.11.01%7 810